The International AIDS Vaccine Initiative (IAVI) issued the following statement from its President and CEO, Dr. Seth Berkley, following the release of the first analysis of the entire study population from a late-stage AIDS vaccine trial, known as the STEP study. The analysis confirmed an earlier analysis of data on half of the 3,000 trial volunteers, released Sept. 21, that concluded the vaccine candidate, manufactured by Merck & Co., was not efficacious.
The Merck candidate neither prevented HIV infection nor lessened the amount of virus in those who became infected. According to the trial co-sponsors, Merck and the HIV Vaccines Trial Network (HVTN), the new analysis suggests that those who received the vaccine, which cannot cause HIV infection, might have an increased susceptibility to acquiring HIV. Volunteers who had prior natural exposure to the Ad5 vector that was used in the vaccine might be particularly susceptible, the trial sponsors said. Responding to the news, which was announced at a special open scientific session at a meeting of the HVTN in Seattle Nov. 7, IAVIís Dr. Berkley said:
ďItís disappointing that the Merck candidate didnít work, but itís important to bear in mind that this was one trial, of one candidate. It is as vital as ever to find an AIDS vaccine, and the effort will continue.
ďIt took 47 years after the polio virus was discovered before a vaccine was developed. Chicken pox took 42 years. Rotavirus, which causes diarrheal disease, took 33. HIV was discovered 24 years ago and weíve only had a serious AIDS vaccine effort for about a decade, with only two candidates tested for efficacy. History tells us it takes a long time to develop a vaccine, but it also tells us itís the only way to eliminate a plague like AIDS. No viral epidemic has been defeated without a vaccine.
ďItís also vital that everybody keeps straight what we know and what we donít know. We know the Merck vaccine didnít work. We donít know why. We know that more people who got the Merck candidate than got the placebo wound up becoming HIV infected. We donít know if that had anything to do with the candidate or not. Given that the trend didnít rise to statistical significance, it could have been chance. And if the vaccine was a factor, we donít know why.
ďOur view is that the results of the Merck trial will require a great deal more study before larger lessons can be drawn from them for the larger AIDS vaccine field.
ďIn the meantime, the news should be absorbed with some perspective. The world owes a debt of gratitude to the STEP trialís sponsors and, most of all, to the study volunteers. Though the Merck candidate failed, the trial did not. The contribution of the volunteers was not in vain. As a result of their dedication, the field will have new data that will inform future vaccine design, help with the prioritization of candidates in the pipeline and guide decisions on how to best proceed with ongoing and upcoming trials.
ďIt is also important to recognize that the failure of the Merck product to prevent HIV infection is not unexpected. Merckís candidate, like nearly all vaccine candidates now in the pipeline, was designed to activate the T-cell arm of the immune system. T-cells work like commando units, travelling through the body, seeking out pathogen-infected cells, which they then kill. Because T-cells only attack cells that are already infected, many scientists, including those at IAVI, think T-cell vaccines are unlikely to protect individuals from becoming infected. Itís more likely T-cell vaccines will reduce the amount of virus in people who, once vaccinated, become infected. In the event, the Merck vaccine did not achieve either result.
ďBecause of this limitation of T-cell vaccines, some scientists in the field, including those at IAVI, in recent years have shifted more resources toward discovery of next-generation candidates, including those that would activate the antibody arm of the immune system. Antibodies act like the bodyís border guards, stopping pathogens from entering the body, and thus preventing infection.
ďWhatever lessons the STEP trial eventually teaches us, one thing is certain: the need for a vaccine has never been greater. The arithmetic hasnít changed. About 39 million people are HIV infected; three million die annually of AIDS. Antiretroviral therapies prolong the lives of those who become infected, but for every person who is put on ARV treatment, there are six new HIV infections. UNAIDS recently estimated that to fulfil the G8ís goal of providing a comprehensive AIDS response, including prevention, treatment and care, to everyone in the developing world who needs it would cost at least $45 billion a year by 2015, more than five times what is being spent today. Spending on AIDS would have to go from a tenth of all overseas development to a third, jeopardizing other development goals. And although ARVs ease the suffering of those who are sick, they will not end the epidemic. Only a vaccine holds out the hope of eliminating AIDS.
ďAnd there are sound scientific reasons to believe we can develop a vaccine against AIDS. The human immune system, it turns out, is better at fighting HIV than weíd originally thought. Most people suppress the virus for many years before developing AIDS. A small number never contract the virus despite repeated exposure. Others are infected but have not developed AIDS. Whatís more, vaccine studies in non-human primates, our closest relatives, show that infection can be prevented entirely. With such strong evidence in humans and in animals, scientists think a vaccine is possible.
ďDeveloping a truly effective, preventive vaccine has been, and will continue to be, an extremely challenging scientific goal. But given the human stakes, we have no choice but to redouble our efforts to realize that goal.
Rachel Steinhardt | Source: EurekAlert!
Further information: www.iavi.org
More articles from Studies and Analyses:
Study uncovers new evidence for assessing tsunami risk from very large volcanic island landslides
11.12.2013 | National Oceanography Centre
Money may corrupt, but thinking about time can strengthen morality
11.12.2013 | Association for Psychological Science
The molecular architecture of three key proteins and their complexes reveals how plants fine-tune their immune response to pathogens
Plants rarely get sick in their natural environment. When the threat of infection arises, a quick decision is made about the necessary countermeasures. The course is set by a protein which forms complexes with its partner proteins for this purpose.
Jane Parker from the Max Planck Institute for Plant Breeding ...
Researchers studying speciation of butterfly orchids on the Azores have been startled to discover that the answer to a long-debated question "Do the islands support one species or two species?" is actually "three species".
Hochstetter's Butterfly-orchid, newly recognized following application of a battery of scientific techniques and reveling in a complex taxonomic history worthy of Sherlock Holmes, is arguably Europe's rarest orchid species. Under threat in its mountain-top retreat, the orchid urgently requires conservation recognition.
A lavishly illustrated publication, titled "Systematic revision of Platanthera in ...
Researchers from Brown University and the University of Hawaii have found some mineralogical surprises in the Moon's largest impact crater.
Data from the Moon Mineralogy Mapper that flew aboard India's Chandrayaan-1 lunar orbiter shows a diverse mineralogy in the subsurface of the giant South Pole Aitken basin.
The differing mineral signatures could be reflective of the minerals dredged up at the time of the giant impact 4 billion years ago, ...
In power electronics systems bonded connections create the central electrical connections between adjoining surfaces.
The quality of these bonded connections is one of the main factors that determines the reliability and availability of drive systems in electric vehicles, and hence constitutes a major design challenge for German auto manufacturers aiming to electrify their vehicles.
Now the partners participating in the RoBE (Robust Bonds in ...
International team of scientists develops new feedback method for optimizing the laser pulse shapes used in the control of chemical reactions
In many ways, traditional chemical synthesis is similar to cooking. To alter the final product, you can change the ingredients or their ratio, change the method of mixing ingredients, or change the temperature or pressure of the environment of the ingredients.
Like an accomplished chef, chemists have become very skilled ...
11.12.2013 | Information Technology
11.12.2013 | Life Sciences
11.12.2013 | Agricultural and Forestry Science
11.12.2013 | Event News
10.12.2013 | Event News
05.12.2013 | Event News